247 related articles for article (PubMed ID: 33244314)
1. ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.
Rao AA; Madejska AA; Pfeil J; Paten B; Salama SR; Haussler D
Front Immunol; 2020; 11():483296. PubMed ID: 33244314
[TBL] [Abstract][Full Text] [Related]
2. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
3. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
Front Immunol; 2021; 12():644637. PubMed ID: 33927717
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
Front Immunol; 2020; 11():373. PubMed ID: 32226429
[TBL] [Abstract][Full Text] [Related]
5. The neoepitope landscape of breast cancer: implications for immunotherapy.
Narang P; Chen M; Sharma AA; Anderson KS; Wilson MA
BMC Cancer; 2019 Mar; 19(1):200. PubMed ID: 30832597
[TBL] [Abstract][Full Text] [Related]
6. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
Front Immunol; 2018; 9():99. PubMed ID: 29441070
[TBL] [Abstract][Full Text] [Related]
7. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
8. Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogenicity Prediction.
Diao K; Chen J; Wu T; Wang X; Wang G; Sun X; Zhao X; Wu C; Wang J; Yao H; Gerarduzzi C; Liu XS
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232923
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
10. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
11. The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community.
Koşaloğlu-Yalçın Z; Blazeska N; Carter H; Nielsen M; Cohen E; Kufe D; Conejo-Garcia J; Robbins P; Schoenberger SP; Peters B; Sette A
Front Immunol; 2021; 12():735609. PubMed ID: 34504503
[TBL] [Abstract][Full Text] [Related]
12. The neoepitope landscape in pediatric cancers.
Chang TC; Carter RA; Li Y; Li Y; Wang H; Edmonson MN; Chen X; Arnold P; Geiger TL; Wu G; Peng J; Dyer M; Downing JR; Green DR; Thomas PG; Zhang J
Genome Med; 2017 Aug; 9(1):78. PubMed ID: 28854978
[TBL] [Abstract][Full Text] [Related]
13. TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes.
Zhang G; Chitkushev L; Olsen LR; Keskin DB; Brusic V
BMC Bioinformatics; 2021 Apr; 22(Suppl 8):40. PubMed ID: 33849445
[TBL] [Abstract][Full Text] [Related]
14. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.
Brennick CA; George MM; Corwin WL; Srivastava PK; Ebrahimi-Nik H
Immunotherapy; 2017 Mar; 9(4):361-371. PubMed ID: 28303769
[TBL] [Abstract][Full Text] [Related]
15. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.
Wu J; Wang W; Zhang J; Zhou B; Zhao W; Su Z; Gu X; Wu J; Zhou Z; Chen S
Front Immunol; 2019; 10():2559. PubMed ID: 31736974
[TBL] [Abstract][Full Text] [Related]
16. nextNEOpi: a comprehensive pipeline for computational neoantigen prediction.
Rieder D; Fotakis G; Ausserhofer M; René G; Paster W; Trajanoski Z; Finotello F
Bioinformatics; 2022 Jan; 38(4):1131-1132. PubMed ID: 34788790
[TBL] [Abstract][Full Text] [Related]
17. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
18. HLA-binding properties of tumor neoepitopes in humans.
Fritsch EF; Rajasagi M; Ott PA; Brusic V; Hacohen N; Wu CJ
Cancer Immunol Res; 2014 Jun; 2(6):522-9. PubMed ID: 24894089
[TBL] [Abstract][Full Text] [Related]
19. Combination therapies utilizing neoepitope-targeted vaccines.
Lee KL; Schlom J; Hamilton DH
Cancer Immunol Immunother; 2021 Apr; 70(4):875-885. PubMed ID: 33033852
[TBL] [Abstract][Full Text] [Related]
20. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.
Leisegang M; Engels B; Schreiber K; Yew PY; Kiyotani K; Idel C; Arina A; Duraiswamy J; Weichselbaum RR; Uckert W; Nakamura Y; Schreiber H
Clin Cancer Res; 2016 Jun; 22(11):2734-43. PubMed ID: 26667491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]